first-in-class oral, allosteric TYK2 inhibitor FDA-approved for moderate-to-severe plaque psoriasis opt. + SBDD of in-house phenotypic HTS hit deucravacitinib (BMS-986165, SOTYKTU) Bristol Myers Squibb, New York, NY